AlphAIalphai — Financial news for AI agents
SEC EDGARMAY 302 min read$PSNL

Hall Christopher M sold $883K of PSNL

Hall Christopher M (Chief Executive Officer) sold 80,091 shares of Personalis, Inc. (PSNL) at $11.02 ($0.88M total) on 2026-05-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Hall Christopher M
Published May 30, 2026, 12:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 30, 2026, 1:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$PSNL
Neutral
medium confidence
Mentioned
$PSNL
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PSNLNeutralLow
01

Why it matters

The disclosure provides transparency on insider liquidity/positioning but does not, by itself, indicate a new negative fundamental development given the pre-arranged nature.

02

Market read

For PSNL, this is primarily a sentiment/insider-activity datapoint; without accompanying company-specific news, trading impact is likely modest.

03

What to watch

Traders may want to compare with prior insider activity patterns (frequency/size) and whether other insiders or institutions are changing positions around the same period.

Relevance 6/10Novelty 6/10Timing: Filed/dated May 29, 2026 (after-hours disclosure timing via SEC EDGAR).

Background

The filing is an SEC Form 4 insider transaction for Personalis, Inc., showing an officer/director sale executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$PSNLNeutralMedium confidence
Context

PSNL CEO Christopher M. Hall sold 80,091 shares (~$882.6K) via an open-market transaction under a 10b5-1 plan, disclosed on SEC Form 4.

Expected impact

Likely limited near-term impact; any reaction may be sentiment-driven rather than fundamentals.

Evidence & confidence

This is a routine insider transaction disclosure with 10b5-1 pre-arrangement, providing a datapoint on insider activity but not a new operating/financial catalyst.

Market effects

Sector

Minimal; single-company insider sale with no stated operational/regulatory change.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a 10b5-1 plan, the market may overreact; price impact could fade quickly if no other catalysts exist.

Key entities

  • issuer
    Personalis, Inc.

    Company whose CEO disclosed an open-market sale of shares via a 10b5-1 plan.

  • insider
    Christopher M. Hall

    CEO and officer/director who sold 80,091 shares at $11.0200/share.

Read at source← All news

Related articles

AUG 5
$PSNLMed

Personalis Reports Second Quarter 2026 Results and Recent Highlights

Personalis (Nasdaq: PSNL) reported Q2 2026 results for the quarter ended June 30. Clinical tests rose 199% to 10,384. Clinical revenue increased 442% to $2.6 million, while total revenue grew 30% to $22.4 million. The company said it secured Medicare coverage for NeXT Personal in additional IO and neoadjuvant breast cancer indications and ended the quarter with about $212.7 million in cash.

biospace.com4 min
AUG 4
$PSNLMedAI 8/10

Personalis, Inc. (PSNL): Results of Operations and Financial Condition

Personalis, Inc. (PSNL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 psnl-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Personalis Reports Second Quarter Results and Recent Highlights Clinical test volume surged 199% year-over-year and 33% sequentially to 10,384 tests in Q2 Clinical revenue grew 442% to $2.6 million and overall revenue grew 30

SEC EDGAR 8-K5 min
JUL 31
$TEMMedAI 8/10

Dear Tempus AI Stock Fans, Mark Your Calendars for July 30

Tempus AI (NASDAQ: TEM) agreed to acquire Personalis (PSNL) for $16.25 per share in stock, valuing the deal at about $1.5 billion enterprise value net of Tempus’ existing stake, with closing expected late 2026 or early 2027. Tempus expects integration to expand MRD capabilities. After the July 20 announcement, TEM fell 7.74% intraday. In Q1, revenue rose 36.1% to $348.12M. Needham reiterated Buy at $75; consensus target is $66.75.

yahoo.com5 min
JUL 24
$TEMMedAI 8/10

Tempus makes $1.5B bet to corner cancer-test market

Tempus AI (TEM) agreed to acquire Personalis (PSNL) for about $1.5 billion, paying $16.25 per Personalis share including debt. The deal gives Tempus full control of the NeXT Personal MRD cancer test. Personalis reported preliminary Q2 revenue of $22.4 million. Tempus stock fell about 9% on July 20 amid expected dilution and delayed closing to late 2026/early 2027.

yahoo.com7 min
JUL 22
$TEMMedAI 8/10

Dollar Bet on the Future of Cancer Monitoring

Tempus AI (NASDAQ:TEM) agreed to acquire Personalis (NASDAQ:PSNL) for $1.5 billion to expand minimal residual disease (MRD) capabilities. Tempus shares recovered after an early selloff. William Blair sees strategic fit and a $20 billion MRD market, but notes a high ~14x 2027 sales multiple and Personalis’ expected 2027 adjusted EBITDA loss of about $90 million. BNP Paribas said the deal could increase pressure on Natera (NASDAQ:NTRA).

sahmcapital.com6 min